Subgroup analysis in clinical trials constitutes a vital methodological tool to uncover differential treatment effects within specified categories of patients. This approach enables researchers to ...
Background Guidelines strongly recommend reperfusion therapy, including thrombolysis and percutaneous coronary intervention, ...
Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181 This study aims to reconstruct unreported ...
Medical announced results from a post-hoc exploratory subgroup analysis of its previously reported first-in-human ...
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic neuroendocrine ...
ALAMEDA, Calif., October 18, 2025--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the CABINET phase 3 pivotal trial evaluating CABOMETYX ® ...
HONG KONG, June 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") presented the subgroup analysis data from the Phase III COMPASSION-16 trial, evaluating cadonilimab, a ...
SEOUL, South Korea, May 29, 2025 /PRNewswire/ --Neuronata-R®, an autologous bone marrow-derived mesenchymal stem cell (MSC) therapy for amyotrophic lateral sclerosis (ALS), has demonstrated meaningful ...
The effect of changes in PSA kinetics on metastasis-free survival (MFS) in patients with PSA-recurrent prostate cancer (PC) treated with nonhormonal agents: Combined analysis of three randomized ...
We appreciate the comments raised by Shirin Heidari and colleagues about the need for better reporting of sex and gender considerations in randomised trials. We agree that these participant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback